Communiqués Pfizer, Inc.

Actions

PFE

US7170811035

Produits pharmaceutiques

Temps réel estimé Cboe BZX Autres places de cotation 18:47:24 16/06/2025			Varia. 5j.	Varia. 1 janv.
24,36 ^USD	-0,75 %		+1,61 %	-8,20 %

13/06	Moderna chute en raison des craintes que le nouveau comité consultatif sur les vaccins du CDC ne compromette les perspectives du vaccin contre le VRS	RE
13/06	Moderna chute en raison des craintes que le nouveau comité consultatif du CDC sur les vaccins ne compromette les perspectives du vaccin contre le VRS	RE

Communiqués

Pfizer : Provides Update on U.S. Regulatory Review of TALZENNA in Combination with XTANDI for Broader Use in Metastatic Castration-Resistant Prostate Cancer	13/06	PU
Pfizer Pflash: A Spotlight on Pfizer's Breast Cancer Portfolio Transcript	13/06	PU
Pfizer : 2024 Impact Report Highlights Accomplishments in Sustainability, Responsibility	13/06	PU
Pfizer Pflash: A Spotlight on Pfizer's Breast Cancer Portfolio Presentation	12/06	PU
Pfizer : Goldman Sachs 46th Annual Global Healthcare Conference Transcript	09/06	PU
Pfizer : Goldman Sachs 46th Annual Global Healthcare Conference Event Announcement	09/06	PU
INVESTIGATION ALERT: Berger Montague PC Investigates Pfizer Inc.'s Board Of Directors For Breach of Fiduciary Duties (NYSE: PFE)	03/06	PR
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference	02/06	BU
Pfizer's BRAFTOVI Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	02/06	AQ
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer	31/05	AQ
Pfizer’s BRAFTOVI® Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer	30/05	BU
Hearing Against Pfizer Set For 30 May In Contraceptive ‘Depo-Provera’ Multidistrict Litigation Overseen By Levin Papantonio	28/05	BU
Pfizer : and BioNTech Submit EMA Application for COVID-19 Vaccine Targeting LP.8.1 for 2025-2026 Season	28/05	PU
Pfizer : First Quarter 2025 Transcript	26/05	PU
Pfizer Enters into Exclusive Licensing Agreement with 3SBio	20/05	BU
Pfizer : Quarterly Corporate Performance - First Quarter 2025 Transcript	30/04	PU
Pfizer : Quarterly Corporate Performance - First Quarter 2025 Prepared Remarks	29/04	PU
Pfizer : Quarterly Corporate Performance - First Quarter 2025 Infographic	29/04	PU
Pfizer : Quarterly Corporate Performance - First Quarter 2025 Press Release	29/04	PU
Pfizer : First Quarter 2025 Earnings Teleconference	29/04	PU
Pfizer: Q1 Earnings Snapshot	29/04	AQ
Pfizer : First Quarter 2025 Infographic	29/04	PU
Pfizer Reports Solid First-Quarter 2025 Results And Reaffirms 2025 Guidance	29/04	BU
Pfizer’s Sasanlimab Combination Significantly Improves Event-Free Survival in BCG-Naïve, High-Risk Non-Muscle Invasive Bladder Cancer	26/04	BU
Pfizer Declares Second-Quarter 2025 Dividend	23/04	BU

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

A la une

Pfizer réduit ses dépenses en raison d'un ralentissement des ventes

Le 29 avril 2025 à 23:02

Pfizer, Inc. : Attaque en règle

Le 08 octobre 2024 à 11:08